Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Atanackovic, Djordje, Luetkens, Tim, Omili, Destiny, Iraguha, Thierry, Lutfi, Forat, Hardy, Nancy M., Fan, Xiaoxuan, Avila, Stephanie V., Saharia, Kapil K., Husson, Jennifer S., Niederhaus, Silke V., Margiotta, Philip, Lee, Seung T., Law, Jennie Y., Mannuel, Heather D., Vander Mause, Erica, Bauman, Sherri, Lesho, Patricia, Hankey, Kim, Baddley, John, Kocoglu, Mehmet, Yared, Jean A., Rapoport, Aaron P., Dahiya, Saurabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Letters to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135504/
https://www.ncbi.nlm.nih.gov/pubmed/35537186
http://dx.doi.org/10.1182/blood.2022016175
Descripción
Sumario:Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.

Ejemplares similares